Hikma Discusses Quality Vs Quantity Approach At Jefferies

The CEO Also Commented On The Potential Impact Of Trump’s Presidency

Hikma aims to launch fewer, but more material, products in the coming years as part of a shift in its research and development strategy that was discussed in a Q&A at this year’s Jefferies Healthcare Conference.

Image of Hikma's logo
• Source: Shutterstock

Hikma Pharmaceuticals is in the midst of a shift in its research and development strategy that will prioritize fewer but higher-value products over a larger number of drugs that represent smaller-scale opportunities, per a Q&A at this year’s Jefferies Healthcare Conference in London in late November.

Attended by Hikma’s chief executive officer Riad Mishlawi and the company’s chief financial officer Khalid Nabilsi, the Q&A session provided...

More from Conferences

More from Generics Bulletin